Degarelix acetate for the treatment of prostate cancer

Drugs of Today

Volumn 45, Issue 10, 2009, Pages 725-730

  Klotz, Laurence ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DEGARELIX; FIRMAGON; LEUPRORELIN; UNCLASSIFIED DRUG;

ANDROGEN DEFICIENCY; ARTHRALGIA; CARDIOVASCULAR DISEASE; CEREBROVASCULAR DISEASE; CHILL; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; DRUG STRUCTURE; DRUG WITHDRAWAL; HUMAN; INJECTION SITE REACTION; PROSTATE CANCER; REVIEW; TREATMENT RESPONSE; TREATMENT WITHDRAWAL; URINARY TRACT INFECTION;

EID: 76749095107     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2009.45.10.1417873     Document Type: Review

References (38)

1. Carroll, P.R., Kantoff, P.W., Balk, S.P. et al. Second International Conference on Newer Approaches to Androgen Deprivation Therapy (ADT) in Prostate Cancer. Overview consensus statement. Newer approaches to androgen deprivation therapy in prostate cancer. Urology 2002, 60(3 Suppl. 1): 1-6.
2. Conn, P.M., Crowley, W.F. Jr. Gonadotrophin-releasing hormone and its analogues. N Engl J Med 1991, 324(2): 93-103.
3. Lepor H. Comparison of single-agent androgen suppression for advanced prostate cancer. Rev Urol 2005, 7(Suppl. 7): S3-S12.
4. Waxman, J., Man, A., Hendry, W.F. Et al. Importance of early tumour exacerbation in patients treated with long acting analogues of gonadotrophin releasing hormone for advanced prostatic cancer. Br Med J 1985, 291(6): 1387-8.
5. Thompson, I.M., Zeidman, E.J., Rodriguez, F.R. Sudden death due to disease flare with luteinizing hormone-releasing hormone agonist therapy for carcinoma of the prostate. J Urol 1990, 144: 1479-80.
6. Boccon-Gibod, L., Laudat, M.H., Dugue, M.A., Steg, A. Cyproterone acetate lead-in prevents initial rise of serum testosterone induced by LHRH analogs in the treatment of metastatic carcinoma of the prostate. Eur Urol 1986, 12(6): 400-2.
7. Morote, J., Orsola, A., Planas, J., Trilla, E., Raventós, C.X., Cecchini, L., Catalán, R. Redefining clinically significant castration concentrations in men receiving continuous androgen deprivation. J Urol 2007, 178(4, Pt. 1): 1290-5.
8. Fluker, M.R. GnRH antagonists. Curr Opin Endocrinol Diabetes 2000, 7: 350-6.
9. Limonta P, Montagnani Marelli M, Moretti RM. LHRH analogues as anticancer agents: Pituitary and extrapituitary sites of action. Expert Opin Investig Drugs 2001, 10(4): 709-20.
10. Broqua, P., Riviere, P.J., Conn, P.M., Rivier, J.E., Aubert, M.L., Junien, J.L. Pharmacological profile of a new, potent, and long-acting gonadotropin-releasing hormone antagonist: Degarelix. J Pharmacol Exp Ther 2002, 301(1): 95-102
11. Princivalle, M., Broqua, P., White, R. et al. Rapid suppression of plasma testosterone levels and tumor growth in the Dunning rat model treated with degarelix, a new gonadotropin-releasing hormone antagonist. J Pharmacol Exp Ther. 2007, 320(3): 1113-8.
12. Jiang, G.C., Stalewski, J., Galyean, R. et al. GnRH antagonists: A new generation of long acting analogues incorporating para-ureido-phenylolanines at positions 5 and 6. J Med Chem 2001, 44: 453-467.
13. Effectiveness and safety of Firmagon® (FAST). (NCT00930319). ClinicalTrials.gov Web Site, Nov 2, 2009.
14. Investigation of the effect of degarelix in terms of prostate volume reduction in prostate cancer patients. (NCT00884273). ClinicalTrials.gov Web Site, Oct 9, 2009.
15. A study evaluating a one-month dosing regimen of degarelix in prostate cancer requiring androgen ablation therapy. (NCT00451958). ClinicalTrials.gov Web Site, June 11, 2009.
16. A study of degarelix in patients with prostate cancer. (NCT00928434). ClinicalTrials.gov Web Site, June 25, 2009.
17. Intermittent treatment with degarelix of patients suffering from prostate cancer. (NCT00801242). ClinicalTrials.gov Web Site, Sept 7, 2009.
18. Neoadjuvant study investigating degarelix in patients suffering from prostate cancer (NCT00833248). ClinicalTrials.gov Web Site, Oct 8, 2009.
19. A trial of degarelix in patients with prostate cancer. (NCT00946920). ClinicalTrials.gov Web Site, July 24, 2009.
20. A long term safety study of degarelix in patients with prostate cancer. (NCT00967018). ClinicalTrials.gov Web Site, Oct 8, 2009.
21. Symptomatic study investigating degarelix in patients suffering from prostate cancer. (NCT00831233). ClinicalTrials.gov Web Site, Sept 14, 2009.
22. Extension study investigating the long-term safety and tolerability of degarelix one-month depots in patients with prostate cancer. (NCT00117286). ClinicalTrials.gov Web Site, Oct 2, 2009.
23. An extension study evaluating the long-term safety and tolerability of degarelix one-month depots in prostate cancer (NCT00215683). ClinicalTrials.gov Web Site, Aug 17, 2009.
24. An open-label, multi-centre, extension study. (NCT00268892). ClinicalTrials.gov Web Site, Aug 24, 2009.
25. Trial to investigate efficacy and safety of degarelix in men with lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH). (NCT00947882). ClinicalTrials.gov Web Site, Oct 9, 2009.
26. Degarelix as second-line hormonal treatment after prostate-specific antigen (PSA)-failure in GnRH agonist treated patients with prostate cancer. (NCT00738673). ClinicalTrials.gov Web Site, Aug 6, 2009.
27. http://www.accessdata.fda.gov/drugsatfda-docs/label/2008/022201lbt.pdf. Accessed Nov 6, 2009.
28. http://www.emea.europa.eu/pdfs/human/opinion/Firmagon-66716208en.pdf. Accessed Nov 6, 2009.
29. http://www.emea.europa.eu/humandocs/Humans/EPAR/firmagon/firmagon.htm. Accessed Nov 6, 2009.
30. Gittelman, M., Pommerville, P.J., Persson, B.E., Jensen, J.K., Olesen, T.K. Degarelix Study Group. A 1-year, open label, randomized phase II dose finding study of degarelix for the treatment of prostate cancer in North America. J Urol 2008, 180(5): 1986-92.
31. Gittelman, M., Pommerville, P.J., Persson, B.E., Olesen, T.K. A multicentre, randomised one year dose-finding study of degarelix, a gonadotropin-releasing hormone (GnRH) receptor blocker, in prostate cancer patients. Urology 2007, 70(Suppl. 3A): Abst MP-08.21.
32. Van Poppel, H., Tombal, B., de la Rosette, J.J., Persson, B.E., Jensen, J.K., Kold Olesen, T. Degarelix: A novel gonadotropin-releasing hormone (GnRH) receptor blocker-results from a 1-yr, multicentre, randomised, phase 2 dosage-finding study in the treatment of prostate cancer. Eur Urol 2008, 54(4): 805-13.
33. Van Poppel, H., De la Rosette, J.J., Persson, B.E., Olesen, T.K. Long-term evaluation of degarelix, a gonadotrophin-releasing hormone (GnRH) receptor blocker, investigated in a multicentre randomised study in prostate cancer (CaP) patients. Eur Urol Suppt 2007, 6(2): Abst 23.
34. Klotz, L., Boccon-Gibod, L., Shore, N.D. et al. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer. BJU Int. 2008, 102(11): 1531-8.
35. Iversen, P., Jensen, J.K., Olesen, T.K., Persson, B.E. Phase III trial of degarelix vs leuprolide: Comparing safety and tolerability. 2nd World Congr Controv Urol (CURy) (Feb 5-8, Lisbon) 2009, Abst 110.
36. Iversen, P., Jensen, J.K., Olesen, T.K., Persson, B.E. Degarelix compared with leuprolide in a 12-month randomized, open-label, parallel-group, phase III study (CS21) in prostate cancer (PCA) patients. 2nd World Congr Controv Urol (CURy) (Feb 5-8, Lisbon) 2009, Abst 111.
37. Tombal, B., Miller, K., Boccon-Gibod, L. et al. Degarelix vs. leuprolide treatment in patients with advanced prostate cancer: PSA failures during a randomised, phase III trial (CS21). Eur Urol Suppl 2009, 8(4): Abst 38.
38. Schröder, F.H., Boccon-Gibod, L., Tombal, B., Miller, K., Jensen, J.K., Olesen, T.K., Persson, B.E. Degarelix versus leuprolide in patients with prostate cancer: Effect in metastatic patients as assessed by serum alkaline phosphatase. Eur Urol Suppl 2009, 8(4): Abst 40.